Pancreatic Cancer Research

ResearcherUniversity of Virginia Health SystemActive in the last 2 years

James M. Lindberg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2250-7163; OpenAlex author ID A5112927041. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 10

  1. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  2. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  3. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  4. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  5. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  6. Utility of HNF-1B and a panel of lineage-specific biomarkers to optimize the diagnosis of pancreatic ductal adenocarcinoma. First author PMID 33791159↗
  7. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. First author DOI 10.1245/s10434-016-5116-4↗
  8. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Co-author DOI 10.1016/j.neo.2014.06.004↗
  9. A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. Co-author DOI 10.1371/journal.pone.0105631↗
  10. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epiderma… First author DOI 10.1593/neo.121712↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jessica N. Everett · 3 shared papers, 2021–2024 · strength 0.33
  2. Aaron J. Grossberg · 3 shared papers, 2021–2024 · strength 0.33
  3. Bryson W. Katona · 3 shared papers, 2021–2024 · strength 0.33
  4. Diane M. Simeone · 3 shared papers, 2021–2024 · strength 0.33
  5. Kasmintan A. Schrader · 3 shared papers, 2021–2024 · strength 0.33
  6. Teresa A. Brentnall · 3 shared papers, 2021–2024 · strength 0.33
  7. Andrew M. Lowy · 3 shared papers, 2021–2024 · strength 0.33
  8. Sonia S. Kupfer · 3 shared papers, 2021–2024 · strength 0.33
  9. Aimee Lee Lucas · 3 shared papers, 2021–2024 · strength 0.33
  10. Salvatore Paiella · 3 shared papers, 2021–2024 · strength 0.33
  11. Daniel C. Chung · 3 shared papers, 2021–2024 · strength 0.33
  12. Yan Bi · 3 shared papers, 2021–2024 · strength 0.33
  13. George Zogopoulos · 3 shared papers, 2021–2024 · strength 0.33
  14. Jennifer B. Permuth · 3 shared papers, 2021–2024 · strength 0.33
  15. Fay Kastrinos · 3 shared papers, 2021–2024 · strength 0.33
  16. Raymond Couric Wadlow · 2 shared papers, 2023–2024 · strength 0.25
  17. Randall E. Brand · 2 shared papers, 2023–2024 · strength 0.25
  18. James J. Farrell · 2 shared papers, 2023–2024 · strength 0.25
  19. Elena M. Stoffel · 2 shared papers, 2023–2024 · strength 0.25
  20. Julie Earl · 2 shared papers, 2023–2024 · strength 0.25
  21. Talia Golan · 2 shared papers, 2021–2024 · strength 0.21
  22. Joy Liau · 2 shared papers, 2021–2024 · strength 0.21
  23. Chenchan Huang · 2 shared papers, 2021–2024 · strength 0.21
  24. Rosalie C. Sears · 2 shared papers, 2021–2024 · strength 0.21
  25. Nipun B. Merchant · 2 shared papers, 2021–2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.